GET DAILY SIGNALSSensus Healthcare (SRTS) Analyst Target of $5.20 Points to +60% Upside
Key Takeaways
- The central target of about $5.20 is the rounded arithmetic mean of three current, verified analyst price targets, not a guarantee of future performance.
- The stock recently traded near $3.20, meaning the target implies roughly 60% upside — a very large move.
- Analyst targets span a wide $4.00 to $6.00 range, reflecting real disagreement about reimbursement timing and customer concentration.
- Supporting factors include new 2026 reimbursement codes, a recurring-revenue "Fair Deal Agreement" model, and a debt-free balance sheet with meaningful cash.
- Key risks include falling quarterly revenue, reliance on a single large customer, and a return to profitability that has been pushed out toward 2027.
- You can find more detail on Major News, Today's Price Move, the Forecast, and Earnings on dedicated pages.
- Explore Trending AI Robots to see how automated AI-driven strategies are tracking stocks and ETFs across the market.
Analyst Price Targets and Consensus View
Sensus Healthcare, Inc. (SRTS) is a medical device company that designs and sells superficial radiation therapy (SRT) systems — most notably the SRT-100/Vision — used to treat non-melanoma skin cancers such as basal cell and squamous cell carcinoma, as well as non-oncological conditions like keloids. It is a stock, not an ETF, and its analyst coverage is relatively thin.
Three current, individually attributed price targets form the basis for the central figure used here. Alliance Global Partners analyst Scott Henry set a $5.50 target with a Buy rating (August 17, 2026), Maxim Group's Anthony Vendetti holds a $6.00 Buy target, and Lake Street's Ben Haynor holds a $4.00 Buy target (August 14, 2026). The arithmetic mean of these three figures is about $5.17, which rounds to a clean $5.20 central target. The range runs from $4.00 to $6.00.
All three ratings are bullish, so the aggregate view reads as a "Strong Buy." However, the direction of recent revisions has been downward: Lake Street trimmed its target from $4.50 to $4.00, and Alliance Global Partners cut from $6.50 to $5.50. Analysts generally cite the SRT platform and new 2026 reimbursement codes as long-term positives, while acknowledging weaker recent results and customer-concentration concerns. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
With the stock recently trading around $3.20 and a market capitalization of roughly $53 million to $56 million, reaching the $5.20 central target would require a gain of about 60%. That is a very large move by any standard, particularly for a company whose trailing earnings per share (EPS) are negative and whose revenue has been contracting.
The path toward the target would likely depend on a genuine operational inflection: re-establishing revenue growth, converting the company's recurring-revenue "Fair Deal Agreement" placements into durable income, and demonstrating that 2026 reimbursement-code changes translate into higher realized pricing and wider adoption. Because the stock trades on a small float and has been volatile — its 52-week range spans roughly $2.64 to $5.43 — even modest news can produce outsized percentage swings in either direction.
What Could Support a Move Toward the Target
- New 2026 reimbursement codes. Analysts and management have pointed to updated CPT codes that can meaningfully raise insurance reimbursement per treatment fraction, potentially improving the economics of SRT adoption.
- Recurring-revenue model. The "Fair Deal Agreement" program places equipment under a recurring-payment structure, which could smooth out lumpy equipment sales over time.
- Balance-sheet strength. The company has been described as holding roughly $18 million in cash with no debt — substantial relative to its market cap and a cushion while it restructures revenue.
- Diversification efforts. Management is deliberately reducing dependence on a single large customer and pursuing international expansion, including MDSAP certification.
What Could Prevent the Target From Being Reached
- Declining revenue. Recent quarterly results have shown sharp year-over-year declines as the company moved away from its largest customer, which previously accounted for the majority of revenue.
- Customer concentration. A single customer reportedly represented roughly 71% of prior-year revenue; rebuilding a diversified base takes time and carries execution risk.
- Delayed profitability. Analysts have pushed expectations for a return to operating profitability out toward 2027, while gross margin has compressed in recent quarters.
- Falling targets. Repeated downward target revisions signal that the market and analysts are pricing in a longer, harder turnaround than previously expected.
Technical Levels and Market Structure
The stock's 52-week range of roughly $2.64 to $5.43 frames the technical picture. The $4.00 mark is notable because it is both the lowest current analyst target and a round-number area the stock has struggled around. Above that, the $5.00 level is a natural psychological hurdle, and the mid-$5 area sits just beneath the 52-week high, a zone where prior selling has emerged. A durable advance toward $5.20 would require the stock to reclaim and hold territory above $4.00 first.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a research horizon of about 12 months, though the specific horizon can vary by firm, and none of the three targets here carries a guaranteed timeline. Investors weighing the $5.20 figure should watch quarterly earnings and revenue, any commentary on the largest customer and the Fair Deal Agreement program, gross-margin trends, and updates on reimbursement-code adoption. Revisions to the three analyst targets — which have been moving lower — will also be an important signal, as will any balance-sheet or capital-allocation updates given the company's meaningful cash position.
AI Daily Buy/Sell Signals
For traders seeking a more dynamic view, Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Rather than relying on a single static price target, the system is designed to help traders discover opportunities, monitor positions, and spot shifting trends more efficiently. Exploring these signals can complement traditional fundamental research when evaluating a volatile small-cap name like Sensus Healthcare.
Final Assessment
Can Sensus Healthcare (SRTS) reach $5.20? The target is the average of three current Buy-rated analyst objectives ($4.00, $5.50, and $6.00), and it sits roughly 60% above the recent price — a demanding threshold for a small-cap medical device company still working through a revenue reset and customer-concentration problem. The bull case rests on new reimbursement codes, a recurring-revenue model, and a clean balance sheet; the bear case centers on shrinking revenue, compressed margins, and a profitability timeline that keeps slipping. With targets already being revised lower, the wide $4.00-to-$6.00 range reflects genuine uncertainty. The next earnings report, revenue trajectory, and any further analyst revisions will be the most important guideposts for whether such a large advance is realistic. From what I see, this remains a high-risk, high-reward setup worth monitoring closely.
Tickeron AI Tools for Research
In my view, tools like Tickeron’s AI Trend Prediction Engine have been helpful for spotting potential inflection points in names like this one, especially when combined with fundamental analysis of reimbursement changes and customer shifts. I often cross-reference signals from the AI Pattern Search Engine as well to get a broader technical context before making decisions on small-cap healthcare stocks.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SRTS in upward trend: price rose above 50-day moving average on November 09, 2026
SRTS moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend. In 36 of 40 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on SRTS as a result. In 79 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for SRTS just turned positive on November 03, 2026. Looking at past instances where SRTS's MACD turned positive, the stock continued to rise in 35 of 39 cases over the following month. The odds of a continued upward trend are 90%.
The 10-day moving average for SRTS crossed bullishly above the 50-day moving average on November 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 88%.
Following a +7.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where SRTS advanced for three days, in 222 of 273 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
The 10-day RSI Indicator for SRTS moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 27 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SRTS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
SRTS broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SRTS entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.277) is normal, around the industry mean (4.142). P/E Ratio (-3.043) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (2.874) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 34 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. SRTS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SRTS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of skin cancer treatment products
Industry MedicalNursingServices
Advertisement